Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium-99m-nanocolloid
- Development stage
- Unknown
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
Technetium-99m-nanocolloid is a radiopharmaceutical diagnostic agent composed of nanometer-sized colloidal particles labeled with the gamma-emitting radionuclide technetium-99m. It is primarily used for sentinel lymph node mapping and identification in various cancers, including breast cancer and vulvar cancer. After injection near a tumor site, the nanocolloids are taken up by lymphatic vessels and accumulate in regional lymph nodes, allowing their detection via single photon emission computed tomography (SPECT) or gamma camera imaging. The mechanism of action relies on the physical decay of technetium-99m by isomeric transition with emission of detectable gamma photons[7][8][3]. This enables precise localization of sentinel lymph nodes draining a primary tumor.
- Brand names
- Nanocoll (GE Healthcare, for human serum albumin-based version)
- Other names
- technetium Tc-99m-labeled nanocolloid99mTc-nanocolloidtechnetium Tc-99m-labeled rhenium sulfide nanocolloid
Beyond the preview
Go deeper on technetium-99m-nanocolloid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium-99m-nanocolloid.